A low AMH result usually suggests that the number of follicles available in the ovaries is lower than expected, particularly when the result is considered alongside age and other fertility findings. It does not, by itself, mean that you are infertile, that your remaining eggs are poor quality, that natural pregnancy is impossible, or that IVF will fail.
Anti-Müllerian hormone is best understood as one part of an ovarian-reserve assessment. Its greatest clinical value is helping fertility specialists estimate how the ovaries may respond to stimulation, especially during IVF. It should therefore be interpreted together with age, menstrual and pregnancy history, ultrasound findings, antral follicle count and the rest of the fertility evaluation.
For someone who has just received an unexpectedly low result, that distinction matters. An AMH number is information not a fertility verdict.
Last updated: 14 September 2026.
AMH, or anti-Müllerian hormone, is produced by cells surrounding small developing follicles in the ovaries. Its blood concentration is used as a marker of ovarian reserve and can help estimate the likely ovarian response to fertility medication.
Ovarian reserve refers mainly to the remaining pool of eggs or oocytes. It is different from egg quality.
This difference is fundamental.
A person can have a relatively small remaining follicle pool but still have eggs capable of fertilisation and developing normally. Conversely, having a higher AMH does not guarantee that every egg is chromosomally normal, that conception will occur quickly, or that a pregnancy will result.
ASRM describes AMH and antral follicle count as useful markers of ovarian reserve and particularly useful for predicting the number of eggs that may be obtained after controlled ovarian stimulation. However, they are much weaker predictors of pregnancy and live birth when considered independently from factors such as age.
Slavica IVF provides both AMH testing and broader ovarian reserve assessment as part of fertility evaluation.
There is no single AMH number that should be interpreted as “low” for every woman. Laboratories, assays, age, medical history and the clinical reason for testing all matter.
This is why interpreting a result simply by comparing it with a number found online can be misleading.
Some research and clinical publications have used specific thresholds to categorize reduced ovarian reserve, but different studies have used different assays and different definitions. The 2025 ESHRE ovarian-stimulation guideline specifically notes this variability while still supporting AMH as a useful predictor of low or high ovarian response.
Age also changes the meaning of the result.
A value that is unexpectedly low in a younger patient may raise different questions from the same value in someone later in reproductive life. WHO’s 2025 infertility guideline emphasizes the importance of age when assessing ovarian reserve and states that age remains an important predictor in this context.
For practical interpretation, ask three questions:
The clinical meaning is more important than attaching a universal label to one number.
The easiest way to understand an AMH result is to separate ovarian reserve, ovarian response, egg quality and pregnancy potential.
| Question | What AMH can tell you | What AMH cannot reliably tell you alone |
|---|---|---|
| How large is my remaining follicle pool? | Gives an indirect estimate of ovarian reserve | Exact number of eggs remaining |
| How may my ovaries respond to IVF stimulation? | Useful predictor of low or high ovarian response | Exact number of usable embryos |
| What is my egg quality? | Very limited information | Whether an individual egg is chromosomally normal |
| Can I become pregnant naturally? | Not a reliable standalone prediction | Whether natural pregnancy will or will not happen |
| Will IVF work? | Can help predict expected egg yield | Whether a cycle will produce a live birth |
| When will menopause happen? | May correlate with reproductive ageing at population level | Precise personal timing of menopause |
This table explains why two people with similar AMH results can have very different fertility experiences.
A lower result may indicate that fewer follicles are likely to respond if the ovaries are stimulated. But pregnancy depends on far more than follicle quantity: age, ovulation, fallopian-tube function, sperm, fertilisation, embryo development, uterine factors and other conditions may all matter.
No. AMH is not a direct egg-quality test.
Ovarian reserve and egg quality are related to reproductive ageing, but they are not the same biological concept. ASRM specifically distinguishes oocyte quantity from oocyte quality and notes that age is considerably more informative than ovarian-reserve testing when estimating reproductive success.
This is one reason statements such as “your AMH is low, therefore your eggs are bad” should be avoided.
A younger woman with diminished ovarian reserve may have fewer recruitable eggs but may still have a meaningful chance of producing competent eggs. A woman with a high AMH can still experience age-related reductions in egg quality.
The number tells one part of the story.
No. A low AMH result is not the same as a diagnosis of infertility.
ACOG cautions against using a single AMH measurement to predict time to pregnancy in women without diagnosed infertility. ASRM similarly concludes that ovarian-reserve markers are poor predictors of natural reproductive potential when used alone.
Infertility evaluation looks at the reproductive system as a whole.
Depending on the situation, that may include menstrual and ovulation history, uterine and tubal assessment, semen analysis, ultrasound, hormone testing and other investigations selected for the individual patient.
Treating one laboratory result as the diagnosis can lead either to unnecessary fear or to inappropriate treatment.
Yes. Natural pregnancy can still occur with low AMH because AMH does not directly measure whether ovulation occurred this month, whether fertilisation can occur, or whether an embryo can implant.
This point often surprises people because AMH is commonly described online as a “fertility test.”
That description is too broad.
ASRM reviewed prospective evidence and concluded that ovarian-reserve markers are poor independent predictors of natural conception. Women with reduced AMH in several studied populations did not necessarily have markedly different short-term natural pregnancy outcomes solely because of that result.
That does not mean low ovarian reserve should be ignored.
The issue is time and context.
A person with reduced reserve may have a smaller follicle pool and therefore potentially less reproductive time available than another person of similar circumstances. Age remains especially important. If pregnancy is desired, clinicians may therefore recommend avoiding unnecessary delays even though natural conception remains possible.
The practical question is not:
“Can someone with low AMH get pregnant?”
The better question is:
“Given my age, ovarian reserve, how long I have been trying, whether I ovulate, my fallopian tubes, my partner’s sperm results and my reproductive plans, what is the most sensible next step?”
That is a much more useful basis for decision-making.
A lower AMH level can occur for different reasons, and sometimes no single cause is identified.
Ovarian reserve generally decreases as reproductive ageing progresses because the ovarian follicle pool gradually declines over time. AMH therefore usually becomes lower with age.
However, women of the same age can have substantially different ovarian-reserve measurements. A result should consequently be interpreted relative to the individual rather than assuming every person follows an identical decline.
Some women simply have a smaller follicle pool than others at the same chronological age.
This does not automatically reveal why the reserve is lower or what the person’s exact fertility outcome will be.
Certain operations involving ovarian tissue can influence ovarian reserve. The relevance depends on the condition being treated, the type of surgery and the amount of functional ovarian tissue affected.
A detailed surgical history is therefore important when interpreting AMH.
Chemotherapy and radiation are among the medical exposures recognized by fertility guidelines as potential risk factors for diminished ovarian reserve. Genetic factors may also be relevant in selected patients. ASRM specifically identifies chemotherapy, radiation exposure and certain genetic conditions among reasons for earlier fertility evaluation.
Hormonal contraception may temporarily reduce measured AMH levels in some patients, so results should be interpreted cautiously in that context rather than automatically assuming a permanent change in ovarian reserve.
This is another reason not to act on the laboratory number without reviewing medications and reproductive history.
AMH works best as part of an assessment rather than as an isolated test.
The next step depends on why the test was performed.
An antral follicle count, or AFC, uses ultrasound to count small follicles visible in the ovaries. AMH and AFC are currently among the most useful measures for predicting ovarian response to stimulation.
The updated ESHRE ovarian-stimulation guideline recommends either AMH or AFC when predicting high or low ovarian response.
When the two results tell a similar story, interpretation is often more straightforward. When they do not, the fertility specialist has to consider the broader clinical picture.
Follicle-stimulating hormone and estradiol may sometimes provide additional information, particularly in certain clinical situations. Unlike AMH, basal FSH and estradiol are generally interpreted at a particular stage of the menstrual cycle.
They should not simply be stacked together as more tests automatically creating more certainty.
ASRM notes that adding multiple ovarian-reserve tests does not consistently improve prediction and can sometimes create confusing discordant results.
Regularity, cycle length and evidence of ovulation matter because ovarian reserve and ovulation are not the same thing.
A person can have reduced reserve and continue to ovulate regularly.
Conversely, someone can have a relatively high AMH but have irregular ovulation, such as in some patients with PCOS.
Ultrasound may help assess the ovaries, follicles, uterus and certain structural conditions.
If infertility is being investigated, fallopian-tube evaluation may also be relevant. An egg cannot meet sperm naturally when both tubes are blocked, regardless of AMH level.
Fertility assessment should not focus only on the female partner.
ASRM recommends parallel evaluation of the male partner when applicable, including semen evaluation as part of the infertility work-up.
This matters because a low AMH result can easily attract all the attention even when another factor has greater influence on treatment choice.
For IVF, AMH is more useful for estimating how the ovaries may respond to stimulation than for predicting whether you will ultimately have a baby.
This is one of the areas where AMH has clear clinical value.
During IVF treatment, fertility medicines are used to recruit multiple follicles. AMH and AFC can help the fertility team anticipate whether the ovaries are likely to produce a lower, average or higher response.
With low ovarian reserve, fewer follicles and eggs may be obtained in one stimulation cycle. That may influence counselling, medication strategy, expectations, and discussions about how many treatment cycles might realistically be needed.
But fewer eggs is not the same thing as zero chance.
ASRM specifically states that even extremely low AMH should not be used by itself to refuse IVF treatment. The test has a much stronger relationship with oocyte yield than with pregnancy or live-birth outcomes.
Consider two hypothetical patients with the same AMH result.
One is 29 and one is 41.
They may both be expected to produce relatively few eggs during stimulation, but the likelihood that each retrieved egg is chromosomally competent may differ substantially because reproductive age strongly affects oocyte quality.
This demonstrates why an AMH number should never replace age in IVF counselling.
Not automatically.
Treatment selection should account for the whole diagnosis.
For some patients, IVF may be recommended sooner because time, age, tubal disease, sperm factors, previous treatment or very low ovarian response makes prolonged lower-intensity treatment less attractive.
For others, natural attempts or IUI may still be reasonable depending on age, sperm results, tubal status, ovulation and how long pregnancy has been delayed.
Slavica’s related guide on whether IVF is always the first option explains why infertility treatment should match the diagnosis instead of automatically progressing to IVF.
AMH should not be treated as an independent IUI success score.
IUI depends on whether ovulation occurs, whether at least one fallopian tube is functional, sperm quality, age, diagnosis and other factors. Ovarian-reserve tests have not shown strong standalone ability to predict pregnancy following ovarian stimulation with IUI for unexplained infertility.
A low result may still influence how long a fertility specialist recommends spending on lower-intensity treatment, especially when age or other time-sensitive factors are present.
That is different from saying, “low AMH means IUI cannot work.”
This is one of the most common questions after an unexpected result.
There is currently no established treatment that reliably restores the underlying ovarian follicle pool simply by raising an AMH laboratory value.
That distinction is important because online fertility content often frames AMH as something that needs to be “boosted.”
The clinical goal is not necessarily to produce a better number on the next blood test. The goal is to understand your reproductive situation and use the available time and treatment options appropriately.
Some measured AMH values can vary, and factors such as hormonal contraception may influence interpretation. But a change in a blood-test value is not automatically evidence that the ovaries have produced a new supply of eggs.
General health still matters when planning pregnancy.
Maintaining an appropriate weight, avoiding tobacco, managing medical conditions and following evidence-based preconception care can support reproductive and pregnancy health. WHO’s infertility guidance also emphasizes health-promoting lifestyle measures as part of fertility care.
However, general fertility health should not be confused with a promise to reverse diminished ovarian reserve.
Be cautious with products advertised as capable of “restoring AMH,” “regrowing eggs,” or guaranteeing pregnancy. Supplements and add-on therapies can have costs, interactions and uncertain evidence.
Slavica’s evidence-based guide to improving fertility provides broader context on lifestyle and fertility.
The most useful response is neither panic nor dismissal. It is structured interpretation.
Check the laboratory result, unit of measurement and reference information.
Do not compare a number from one assay directly with an unrelated chart from the internet without professional interpretation.
Age is one of the strongest factors affecting fertility and reproductive planning.
The same AMH value can carry different practical implications at different ages.
Was AMH measured because you have been trying unsuccessfully to conceive?
Was it part of preparation for IVF?
Were you considering egg freezing?
Was it ordered as part of a general health package even though you have never tried to conceive?
The appropriate interpretation changes with the reason for testing.
ACOG specifically cautions against using a single AMH measurement as a general fertility forecast in women who are not experiencing infertility.
Depending on your circumstances, a fertility evaluation may include antral follicle count, ovulation assessment, ultrasound, reproductive history, semen analysis and evaluation of the fallopian tubes or uterine cavity.
A low AMH result does not tell you whether sperm are healthy or whether the fallopian tubes are open.
Someone hoping to become pregnant now needs different counselling from someone planning pregnancy several years later.
Your desired family size can also matter. Planning for one child is different from hoping for several pregnancies over many years.
Possible pathways can range from continued natural attempts through ovulation treatment, IUI, IVF or fertility-preservation discussions.
The correct pathway depends on the complete clinical picture.
If trying naturally or using a lower-intensity treatment, ask the specialist:
“How long should we continue before reassessing?”
A defined timeline can prevent months of uncertainty.
For couples without known fertility risk factors, ASRM recommends fertility evaluation after about 12 months of trying when the female partner is under 35, and after about 6 months from age 35 onward. More immediate evaluation may be appropriate over age 40 or when a known fertility problem is present.
A low AMH result may itself justify discussing your reproductive plans earlier rather than assuming the standard waiting period is appropriate in every case.
Earlier assessment is also particularly reasonable when there are factors such as irregular or absent periods, suspected endometriosis, previous pelvic or ovarian surgery, chemotherapy or radiation exposure, known tubal disease, significant male-factor concerns or a family history suggesting unusually early menopause.
The purpose of earlier assessment is not to frighten someone into treatment.
It is to avoid losing useful decision-making time.
A good fertility consultation should explain the result rather than simply label it abnormal.
Useful questions include:
These questions move the discussion from “Is my AMH bad?” to “What decision does this information help us make?”
That is the more useful role of ovarian-reserve testing.
For patients in Nepal, a low AMH result can be evaluated as part of a broader fertility assessment rather than as an isolated blood-test interpretation.
Slavica IVF & Research Center in Sinamangal, Kathmandu lists AMH testing, ovarian reserve testing, follicular monitoring, ultrasound-related assessment, semen analysis, fertility treatment, IUI and IVF within its reproductive-care services.
The fertility department includes Dr. Nikita Dhakal, MD, Obstetrics & Gynaecology, IVF Specialist, along with clinical embryology and genetics expertise.
A consultation is most useful when you bring your actual laboratory report, previous scans or fertility tests, menstrual history, previous pregnancy or treatment information and relevant medical or surgical records.
If you have received a low AMH result, you do not need to assume that pregnancy is impossible or that IVF is automatically required.
You do need to understand what the result means in your clinical context.
A fertility specialist can review your age, AMH, antral follicle count, reproductive history and other fertility factors and explain whether you should continue trying naturally, investigate further, consider IUI, discuss IVF or review fertility-preservation options.
You can book a fertility consultation with Slavica IVF to discuss the result and appropriate next steps.
Low AMH is best understood as a marker associated with ovarian reserve and expected ovarian response, not as a standalone measure of fertility.
It may suggest that fewer follicles are available or that fewer eggs could be retrieved during ovarian stimulation. It does not reveal the precise number of eggs remaining, directly measure egg quality, prove infertility, predict natural conception with certainty or determine whether IVF will result in a baby.
Age remains essential when interpreting reproductive potential. AMH should therefore be considered alongside antral follicle count, medical history, ovulation, sperm, fallopian tubes, previous treatment and reproductive goals.
Most importantly, do not make a major fertility decision from one laboratory value alone.
Use the result to ask better questions and to build a clearer fertility plan.
Yes. Low AMH does not make natural pregnancy impossible. AMH is mainly a marker of ovarian reserve and has limited value for predicting spontaneous conception by itself. Age, ovulation, sperm health, tubal function and other reproductive factors also influence the chance of pregnancy.
No. Low AMH and infertility are not the same diagnosis. A reduced result may indicate lower ovarian reserve or an anticipated lower response to ovarian stimulation, but it does not independently establish whether someone can conceive. A complete fertility evaluation is required when infertility is suspected.
No. AMH primarily reflects egg quantity/ovarian reserve rather than egg quality. Age is much more relevant when estimating age-related changes in egg quality and reproductive potential.
There is no single universal cutoff that should be applied to every patient. Different laboratories, assays, studies and fertility programmes can use different reference points. AMH should therefore be interpreted relative to age, antral follicle count, treatment goals and the laboratory method used.
Not necessarily. Whether IVF is appropriate depends on age, how long pregnancy has been delayed, ovulation, fallopian-tube status, semen results, previous treatments and reproductive goals. Some people may still try naturally or consider IUI, while others may benefit from earlier IVF.
There is no established diet, supplement or lifestyle intervention proven to regenerate the ovarian follicle pool simply by increasing AMH. Healthy lifestyle measures remain important for general reproductive and pregnancy health, but claims that a product can “restore egg reserve” should be treated cautiously.
Yes, measured AMH can vary to some degree, and circumstances such as hormonal contraception may affect levels. A difference between two tests should therefore be interpreted in context rather than assumed to represent a major biological change in egg supply.
Both can be useful. The updated ESHRE ovarian-stimulation guideline recommends either AMH or AFC for predicting low or high response to ovarian stimulation; one is not automatically necessary simply because the other was performed.
Yes, IVF can still be considered. Very low AMH may predict fewer eggs from stimulation, but ASRM states that extremely low AMH should not by itself be used to deny IVF treatment. Outcomes depend on several additional factors, including age, egg and sperm factors, embryo development and laboratory/treatment variables.
Not precisely. AMH declines with reproductive ageing, but a single result should not be used to give an individual an exact menopause date. ACOG notes that evidence is insufficient for using AMH as a precise individual predictor of time to menopause.
